Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.

27. august 2008 opdateret af: Henogen

A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1, 6 Months to That of GSK Biologicals' Adjuvanted Hepatitis B Vaccine Given at 0, 1, 2, 6 Moths in Pre-Dialysis, and Dialysis Patients Who Are Hepatitis B Naive.

The pre-dialysis, peritoneal dialysis and haemodialysis patients would benefit from an improved hepatitis B vaccine, which will elicit stronger and faster cellular and humoral immune responses after the primary vaccination course.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Study participants will receive either Henogen's adjuvanted hepatitis B vaccine or GSK Biologicals' adjuvanted hepatitis B vaccine. The study involves a total of 7 visits and blood samples will taken at each of these visits.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

300

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • ATH, Belgien, 7800
        • RHMS La Madeleine ATH
      • Aalst, Belgien, 9300
        • O.L.Vrouwziekenhuis Aalst
      • Baudour, Belgien, 7331
        • RHMS Clinique Louis Caty Baudour
      • Bruxelles, Belgien, 1200
        • Cliniques Universitaires Saint Luc
      • Bruxelles, Belgien, B-1020
        • CHU Brugmann (site V Horta) Service de néphrologie
      • Bruxelles, Belgien
        • ULB Hôpital Erasme Département de Néphrologie
      • Bruxelles, Belgien, 1090
        • AZ -VUB Dienst Nefrologie
      • Charleroi, Belgien, 6000
        • CHU Hôpital civil de
      • Edegem, Belgien, B-2650
        • UZ AntwerpenDienst nefrologie
      • Gent, Belgien, 9000
        • UZ Gent
      • La Louvière, Belgien, 7100
        • CHU Tivoli
      • Leuven, Belgien, 3000
        • UZ Gasthuisberg Leuven Nierziekten
      • Montigny le tilleul, Belgien, 6110
        • CHU Andre VESALE
      • Tournai, Belgien, 7500
        • RHMS TournayService de néphrologie
      • Jihlava, Tjekkiet, 59586 33
        • Dept. of Heamodialysis Hospital JihlavaVrchlického
      • Liberec, Tjekkiet, 46063
        • Regional Hospital Liberec
      • Ostrava - Poruba, Tjekkiet, 1790708 52
        • Infection Diseases and AIDS Treatment ClinicUniversity Hospital with Outpatient Clinic
      • Prague, Tjekkiet, 169 00
        • Dept. of Internal Medicine StrahovSermirska 5
      • Usti nad Labem, Tjekkiet, 401 13
        • Masaryk´s Hospital Socialni pece 3316/12A
      • Budapest, Ungarn, 1096
        • St. István Hospital
      • Budapest, Ungarn, 1085
        • St. Rókus Hospital
      • Győr, Ungarn, H-9023
        • Petz Aladár Teaching Hospital Vasvári
      • Kistarcsa, Ungarn, 2143
        • Pest County Flór Ferenc Hospital
      • Szombathely, Ungarn, 9700
        • Vas and Szombathely County Markusovszky Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

15 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • A male or female subject 15 years of age or older at the time of the study entry.
  • Written informed consent obtained from the subject/ from the parent or guardian of the subject.
  • Seronegative for anti-HBs antibodies, anti-HBc antibodies and for HBsAg at screening.
  • Pre-dialysis patients, peritoneal dialysis patients or haemodialysis patients.
  • Non-childbearing potential female

Exclusion Criteria:

  • Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Use of any registered vaccine within 7 days before the first dose of study vaccine.
  • Previous vaccination against hepatitis B (whether or not the subject responded to the vaccine).
  • History of hepatitis B infection.
  • Known exposure to hepatitis B virus within 6 months.
  • Use of immunoglobulins within six months preceding the first study vaccination.
  • Immunosuppression caused by the administration of parenteral steroids or chemotherapy (oral steroids are allowed).
  • Any confirmed or suspected human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral/ axillary temperature < 37.5°C (or 37 °C in Czech Republic).
  • Oral/axillary temperature superior or equal to 37.5°C (or 37 °C in Czech Republic).
  • Pregnant or lactating female

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
Henogen HB vaccine
20µg, Month 0, 2 and 6
Aktiv komparator: 2
Fendrix vaccine
20 µg,Months 0, 1, 2 and 6

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Anti-HBs seroprotection rate at Month 2.
Tidsramme: Month 0 and 2
Month 0 and 2

Sekundære resultatmål

Resultatmål
Tidsramme
Anti-HBs antibody concentrations
Tidsramme: Months 0, 1, 2, 3, 6 and 7
Months 0, 1, 2, 3, 6 and 7
Anti-HBs seroprotection rates for all subjects.
Tidsramme: Months 0, 1, 2, 3, 6 and 7
Months 0, 1, 2, 3, 6 and 7
Anti-HBs seropositivity rates for all subjects
Tidsramme: Months 0, 1, 2, 3, 6 and 7
Months 0, 1, 2, 3, 6 and 7
Percentage of subjects with anti-HBs antibody concentrations equal or greater than 100 mIU/ml for all subjects.
Tidsramme: Months 0, 1, 2, 3, 6 and 7
Months 0, 1, 2, 3, 6 and 7
Anti-HBs geometric mean concentrations calculated for all subjects.
Tidsramme: Months 0, 1, 2, 3, 6 and 7
Months 0, 1, 2, 3, 6 and 7
Anti-RF-1 seropositivity rates (defined as the percentage of subjects with anti-RF-1 like antibody concentrations superior or equal to 33 EU/ml, the assay cut-off) in a random subset of 50 subjects per group.
Tidsramme: Months 0 and 7
Months 0 and 7
Anti-RF-1 like antibody geometric mean concentration in a random subset of 50 subjects per group.
Tidsramme: Month 0 and 7
Month 0 and 7
Occurrence and intensity of solicited local signs and symptoms, as well as occurrence, intensity and relationship to vaccination of solicited general signs and symptoms during a 4-day follow-up (i.e. Day 0 to Day 3) after each vaccination and overall.
Tidsramme: Month 0, 1, 2, 3, 6 and 7
Month 0, 1, 2, 3, 6 and 7
Occurrence, intensity and relationship to vaccination of unsolicited symptoms reported during the 31-day (Day 0 to Day 30) follow-up period after each vaccination and overall.
Tidsramme: Month 0, 1, 2, 3, 6 and 7
Month 0, 1, 2, 3, 6 and 7
Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs) up to Month 7.
Tidsramme: Month 0 to 7
Month 0 to 7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Christian Tielemans, MD, PhD, ULB Hôpital Erasme Département de Néphrologie

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. februar 2006

Primær færdiggørelse (Faktiske)

1. marts 2007

Studieafslutning (Faktiske)

1. marts 2007

Datoer for studieregistrering

Først indsendt

14. februar 2006

Først indsendt, der opfyldte QC-kriterier

14. februar 2006

Først opslået (Skøn)

15. februar 2006

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

28. august 2008

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. august 2008

Sidst verificeret

1. august 2008

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner